ALTA DOSE DI 5-FLUOROURACILE (5-FU) PIU L-LEUCOVORIN (L-LV) IN INFUSIONE CONTINUA DI 24 ORE NEL CARCINOMA DEL COLON-RETTO IN FASE METASTATICA

DATI PRELIMINARI

Translated title of the contribution: Concurrent high dose 5-fluorouracil (5-FU) 24-hours infusion and oral L-leucovorin (L-LV) in advanced colorectal cancer: Preliminary data

M. C. Barzacchi, O. Sanguineti, M. T. Nobile, S. Bertoglio, P. M. Meszaros, G. B. Forno, R. Rosso, P. L. Percivale

Research output: Contribution to journalArticle

Abstract

5-FU biochemical modulation remains the most effective treatment in advanced colorectal cancer. In particular, association with folinic acid has reached tumor response rate ranging from 20 to 40%. However similar or higher results have been also observed by modifying pharmacological scheduling, in fact 5-FU protracted or 24 hours continuous infusion has obtained therapeutic efficacy even superior to 50%. On these bases we performed a phase II study with L-LV combined with 5-FU given by 24 hours infusion weekly. Patients with advanced, colorectal carcinoma were elegible; all pts required subcutaneous port insertion and portable external infusions pumps to allow outpatient treatment. Therapy was given as follows: L-LV 100 mg/sqm by 4 hrs infusion followed by 5-FU 2600 mg/sqm over 24 hrs continuous infusion combined with a fixed dose of oral L-LV (50 mg) every 4 hrs for 5 times. Thirty pts entered the study and 23 were evaluable for response: 23 male, 9 female; median age 57; median PS (ECOG) 1; 9 pts had received prior chemotherapy for advanced disease and 10 had received adjuvant chemotherapy. We observed: 1 complete response, 5 partial responses (26% OR), 1 minor response, 11 stable disease and 5 progressions. Most relevant toxicity observed till now is represented by: hand-foot syndrome grade I-II in 13 pt and grade III in 1 pt, reversible with treatment interruption; diarrhea grade III in 5 pts and grade II in 2 pts; fatigue grade III in 2 pts and grade II in 13 pts. Mielotoxicity, alopecia, nausea and vomiting were seen occasionaly. This treatment seems to show good activity regardless pts pre-treatment status, however, because of the recorded toxicity, it needs of further investigation and adequate clinical monitoring.

Original languageItalian
Pages (from-to)17-20
Number of pages4
JournalGiornale Italiano di Oncologia
Volume14
Issue number1
Publication statusPublished - Jan 1 1994

Fingerprint

Leucovorin
Fluorouracil
Colorectal Neoplasms
Therapeutics
Hand-Foot Syndrome
Infusion Pumps
Alopecia
Adjuvant Chemotherapy
Nausea
Vomiting
Fatigue
Disease Progression
Diarrhea
Outpatients
Pharmacology
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Cancer Research

Cite this

Barzacchi, M. C., Sanguineti, O., Nobile, M. T., Bertoglio, S., Meszaros, P. M., Forno, G. B., ... Percivale, P. L. (1994). ALTA DOSE DI 5-FLUOROURACILE (5-FU) PIU L-LEUCOVORIN (L-LV) IN INFUSIONE CONTINUA DI 24 ORE NEL CARCINOMA DEL COLON-RETTO IN FASE METASTATICA: DATI PRELIMINARI. Giornale Italiano di Oncologia, 14(1), 17-20.

ALTA DOSE DI 5-FLUOROURACILE (5-FU) PIU L-LEUCOVORIN (L-LV) IN INFUSIONE CONTINUA DI 24 ORE NEL CARCINOMA DEL COLON-RETTO IN FASE METASTATICA : DATI PRELIMINARI. / Barzacchi, M. C.; Sanguineti, O.; Nobile, M. T.; Bertoglio, S.; Meszaros, P. M.; Forno, G. B.; Rosso, R.; Percivale, P. L.

In: Giornale Italiano di Oncologia, Vol. 14, No. 1, 01.01.1994, p. 17-20.

Research output: Contribution to journalArticle

Barzacchi, MC, Sanguineti, O, Nobile, MT, Bertoglio, S, Meszaros, PM, Forno, GB, Rosso, R & Percivale, PL 1994, 'ALTA DOSE DI 5-FLUOROURACILE (5-FU) PIU L-LEUCOVORIN (L-LV) IN INFUSIONE CONTINUA DI 24 ORE NEL CARCINOMA DEL COLON-RETTO IN FASE METASTATICA: DATI PRELIMINARI', Giornale Italiano di Oncologia, vol. 14, no. 1, pp. 17-20.
Barzacchi, M. C. ; Sanguineti, O. ; Nobile, M. T. ; Bertoglio, S. ; Meszaros, P. M. ; Forno, G. B. ; Rosso, R. ; Percivale, P. L. / ALTA DOSE DI 5-FLUOROURACILE (5-FU) PIU L-LEUCOVORIN (L-LV) IN INFUSIONE CONTINUA DI 24 ORE NEL CARCINOMA DEL COLON-RETTO IN FASE METASTATICA : DATI PRELIMINARI. In: Giornale Italiano di Oncologia. 1994 ; Vol. 14, No. 1. pp. 17-20.
@article{1d1034616e54424abe27ef160cb2b5c4,
title = "ALTA DOSE DI 5-FLUOROURACILE (5-FU) PIU L-LEUCOVORIN (L-LV) IN INFUSIONE CONTINUA DI 24 ORE NEL CARCINOMA DEL COLON-RETTO IN FASE METASTATICA: DATI PRELIMINARI",
abstract = "5-FU biochemical modulation remains the most effective treatment in advanced colorectal cancer. In particular, association with folinic acid has reached tumor response rate ranging from 20 to 40{\%}. However similar or higher results have been also observed by modifying pharmacological scheduling, in fact 5-FU protracted or 24 hours continuous infusion has obtained therapeutic efficacy even superior to 50{\%}. On these bases we performed a phase II study with L-LV combined with 5-FU given by 24 hours infusion weekly. Patients with advanced, colorectal carcinoma were elegible; all pts required subcutaneous port insertion and portable external infusions pumps to allow outpatient treatment. Therapy was given as follows: L-LV 100 mg/sqm by 4 hrs infusion followed by 5-FU 2600 mg/sqm over 24 hrs continuous infusion combined with a fixed dose of oral L-LV (50 mg) every 4 hrs for 5 times. Thirty pts entered the study and 23 were evaluable for response: 23 male, 9 female; median age 57; median PS (ECOG) 1; 9 pts had received prior chemotherapy for advanced disease and 10 had received adjuvant chemotherapy. We observed: 1 complete response, 5 partial responses (26{\%} OR), 1 minor response, 11 stable disease and 5 progressions. Most relevant toxicity observed till now is represented by: hand-foot syndrome grade I-II in 13 pt and grade III in 1 pt, reversible with treatment interruption; diarrhea grade III in 5 pts and grade II in 2 pts; fatigue grade III in 2 pts and grade II in 13 pts. Mielotoxicity, alopecia, nausea and vomiting were seen occasionaly. This treatment seems to show good activity regardless pts pre-treatment status, however, because of the recorded toxicity, it needs of further investigation and adequate clinical monitoring.",
keywords = "5-FU + L-LV, continuous infusion, metastatic colorectal cancer",
author = "Barzacchi, {M. C.} and O. Sanguineti and Nobile, {M. T.} and S. Bertoglio and Meszaros, {P. M.} and Forno, {G. B.} and R. Rosso and Percivale, {P. L.}",
year = "1994",
month = "1",
day = "1",
language = "Italian",
volume = "14",
pages = "17--20",
journal = "Giornale Italiano di Oncologia",
issn = "0392-128X",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "1",

}

TY - JOUR

T1 - ALTA DOSE DI 5-FLUOROURACILE (5-FU) PIU L-LEUCOVORIN (L-LV) IN INFUSIONE CONTINUA DI 24 ORE NEL CARCINOMA DEL COLON-RETTO IN FASE METASTATICA

T2 - DATI PRELIMINARI

AU - Barzacchi, M. C.

AU - Sanguineti, O.

AU - Nobile, M. T.

AU - Bertoglio, S.

AU - Meszaros, P. M.

AU - Forno, G. B.

AU - Rosso, R.

AU - Percivale, P. L.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - 5-FU biochemical modulation remains the most effective treatment in advanced colorectal cancer. In particular, association with folinic acid has reached tumor response rate ranging from 20 to 40%. However similar or higher results have been also observed by modifying pharmacological scheduling, in fact 5-FU protracted or 24 hours continuous infusion has obtained therapeutic efficacy even superior to 50%. On these bases we performed a phase II study with L-LV combined with 5-FU given by 24 hours infusion weekly. Patients with advanced, colorectal carcinoma were elegible; all pts required subcutaneous port insertion and portable external infusions pumps to allow outpatient treatment. Therapy was given as follows: L-LV 100 mg/sqm by 4 hrs infusion followed by 5-FU 2600 mg/sqm over 24 hrs continuous infusion combined with a fixed dose of oral L-LV (50 mg) every 4 hrs for 5 times. Thirty pts entered the study and 23 were evaluable for response: 23 male, 9 female; median age 57; median PS (ECOG) 1; 9 pts had received prior chemotherapy for advanced disease and 10 had received adjuvant chemotherapy. We observed: 1 complete response, 5 partial responses (26% OR), 1 minor response, 11 stable disease and 5 progressions. Most relevant toxicity observed till now is represented by: hand-foot syndrome grade I-II in 13 pt and grade III in 1 pt, reversible with treatment interruption; diarrhea grade III in 5 pts and grade II in 2 pts; fatigue grade III in 2 pts and grade II in 13 pts. Mielotoxicity, alopecia, nausea and vomiting were seen occasionaly. This treatment seems to show good activity regardless pts pre-treatment status, however, because of the recorded toxicity, it needs of further investigation and adequate clinical monitoring.

AB - 5-FU biochemical modulation remains the most effective treatment in advanced colorectal cancer. In particular, association with folinic acid has reached tumor response rate ranging from 20 to 40%. However similar or higher results have been also observed by modifying pharmacological scheduling, in fact 5-FU protracted or 24 hours continuous infusion has obtained therapeutic efficacy even superior to 50%. On these bases we performed a phase II study with L-LV combined with 5-FU given by 24 hours infusion weekly. Patients with advanced, colorectal carcinoma were elegible; all pts required subcutaneous port insertion and portable external infusions pumps to allow outpatient treatment. Therapy was given as follows: L-LV 100 mg/sqm by 4 hrs infusion followed by 5-FU 2600 mg/sqm over 24 hrs continuous infusion combined with a fixed dose of oral L-LV (50 mg) every 4 hrs for 5 times. Thirty pts entered the study and 23 were evaluable for response: 23 male, 9 female; median age 57; median PS (ECOG) 1; 9 pts had received prior chemotherapy for advanced disease and 10 had received adjuvant chemotherapy. We observed: 1 complete response, 5 partial responses (26% OR), 1 minor response, 11 stable disease and 5 progressions. Most relevant toxicity observed till now is represented by: hand-foot syndrome grade I-II in 13 pt and grade III in 1 pt, reversible with treatment interruption; diarrhea grade III in 5 pts and grade II in 2 pts; fatigue grade III in 2 pts and grade II in 13 pts. Mielotoxicity, alopecia, nausea and vomiting were seen occasionaly. This treatment seems to show good activity regardless pts pre-treatment status, however, because of the recorded toxicity, it needs of further investigation and adequate clinical monitoring.

KW - 5-FU + L-LV

KW - continuous infusion

KW - metastatic colorectal cancer

UR - http://www.scopus.com/inward/record.url?scp=0028284102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028284102&partnerID=8YFLogxK

M3 - Articolo

VL - 14

SP - 17

EP - 20

JO - Giornale Italiano di Oncologia

JF - Giornale Italiano di Oncologia

SN - 0392-128X

IS - 1

ER -